Understanding aberrant white matter development in schizophrenia: An avenue for therapy?

Expert Review of Neurotherapeutics

Volumn 11, Issue 7, 2011, Pages 971-987

  Walterfang, Mark ^a,b   Velakoulis, Dennis ^a,b   Whitford, Thomas J ^b   Pantelis, C H Ristos ^b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

antipsychotic medication; dysmyelination; myelin; oligodendrocytes; promyelinative; schizophrenia; white matter

Indexed keywords

6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; GLATIRAMER; HALOPERIDOL; LITHIUM; MEMANTINE; MYELIN; NEUROLEPTIC AGENT; OLANZAPINE; TOPIRAMATE;

ADD ON THERAPY; BRAIN DEVELOPMENT; BRAIN SIZE; DIFFUSION TENSOR IMAGING; DNA POLYMORPHISM; GENE EXPRESSION; HUMAN; MICROARRAY ANALYSIS; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIA; REVIEW; SCHIZOPHRENIA; VOXEL BASED MORPHOMETRY; WHITE MATTER;

ANIMALS; AXONS; BRAIN; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MYELIN SHEATH; NEUROGENESIS; OLIGODENDROGLIA; SCHIZOPHRENIA;

EID: 79959926731     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.11.76     Document Type: Review

References (261)

1. Kanaan R, Kim J, Kaufmann W, Pearlson G, Barker G, Mcguire P. Diffusion tensor imaging in schizophrenia. Biol. Psychiatry 58(12), 921-929 (2005). (Pubitemid 41790701)
2. Kubicki M, Mccarley R, Westin CF et al. A review of diffusion tensor imaging studies in schizophrenia. J. Psychiatr. Res. 41(1-2), 15-30 (2007). (Pubitemid 44780754)
3. Walterfang M, Wood S, Velakoulis D, Pantelis C. Neuropathological, neurogenetic and neuroimaging evidence for white matter pathology in schizophrenia. Neurosci. Biobehav. Rev. 30, 918-948 (2006 (Pubitemid 44292852)
4. Shenton ME, Whitford TJ, Kubicki M. Structural neuroimaging in schizophrenia: from methods to insights to treatments. Dialogues Clin. Neurosci. 12(3), 317-332 (2010
5. Walterfang M, Wood S, Velakoulis D, Copolov D, Pantelis C. Diseases of white matter and schizophrenia-like psychosis. Aust. NZ J. Psychiatry 39, 746-756 (2005 (Pubitemid 43904468)
6. Friston K. Schizophrenia and the disconnection hypothesis. Acta Psychiatrica Scand. Suppl. 99, 68-79 (1999 (Pubitemid 29151867)
7. Friston K. The disconnection hypothesis. Schizophr. Res. 30, 115-125 (1998). (Pubitemid 28156976)
8. Wernicke C. [Outline of Psychiatry. 2nd Edition]. Thieme, Leipzig (1906).
9. Pantelis C, Barnes T, Nelson H. Is the concept of frontal-subcortical dementia relevant to schizophrenia? Br. J. Psychiatry 160, 442-460 (1992).
10. Andreasen N, Paradiso S, Oleary D. Cognitive dysmetria as an integrative theory of schizophrenia: a dysfunction in cortical-subcortical-cerebellar circuitry? Schizophr. Bull. 24, 203-218 (1998). (Pubitemid 28404981)
11. Crow T. Schizophrenia as a transcallosal misconnection syndrome. Schizophr. Res. 30, 111-114 (1998). (Pubitemid 28156975)
12. Schoenemann P, Sheehan M, Glotzer L. Prefrontal white matter volume is disproportionately larger in humans than in other primates. Nature Neurosci. 8, 242-252 (2005). (Pubitemid 40194056)
13. Nolte N. The Human Brain. Mosby, MO, USA (1999).
14. Byrd S, Darling C, Wilczynski M. White matter of the brain: maturation and myelination of magnetic resonance in infants and children. Neuroimag. Clin. N. Am. 3, 247-266 (1993). (Pubitemid 23186222)
15. Yakovlev P, Lecours A. The myelogenetic cycles of regional maturation of the brain. In:Regional Development of the Brain in Early Life. Minkowski A (Ed.). FA Davis, PA, USA, 3-70 (1967).
16. Webb SJ, Monk CS, Nelson CA. Mechanisms of postnatal neurobiological development: implications for human development. Dev. Neuropsychol. 19(2), 147-171 (2001). (Pubitemid 32845926)
17. Barkovich AJ. Concepts of myelin and myelination in neuroradiology. AJNR Am. J. Neuroradiol. 21(6), 1099-1109 (2000). (Pubitemid 30390551)
18. Barkovich AJ, Kjos BO, Jackson DE Jr, Norman D. Normal maturation of the neonatal and infant brain: MR imaging at 1.5 T. Radiology 166(1 Pt 1), 173-180 (1988). (Pubitemid 18027067)
19. Bartzokis G, Beckson M, Lu P, Nuechterlein K, Edwards N, Mintz J. Age-related changes in frontal and temporal lobe volumes in men: a magnetic resonance imaging study. Arch. Gen. Psychiatr. 58, 461-465 (2001). (Pubitemid 32411326)
20. Benes F, Turtle M, Khan Y, Farol P. Myelination of a key relay zone in the hippocampal formation occurs in the human brain during childhood, adolescence, and adulthood. Arch. Gen. Psychiatr. 51, 477-484 (1994 (Pubitemid 24180494)
21. Lim K, Zipursky R, Watts M, Pfefferbaum A. Decreased gray matter in normal aging: an in vivo magnetic resonance study. J. Gerontol. 47, B26-B30 (1992).
22. Pfefferbaum A, Mathalon D, Sullivan E, Al E. A quantitative magnetic resonance imaging study of changes in brain morphology from infancy to late adulthood. Arch. Neurol. 51, 874-887 (1994). (Pubitemid 24286042)
23. Okusky J, Colonnier M. Postnatal changes in the number of astrocytes, oligodendrocytes, and microglia in the visual cortex (area 17) of the macaque monkey: a stereological analysis in normal and monocularly deprived animals. J. Comp. Neurol. 210(3), 307-315 (1982). (Pubitemid 12036973)
24. Elvidge A, Reed G. Biopsy studies of cerebral pathologic changes in schizophrenia and manic-depressive psychosis. Arch. Neurol. Psychiatry 40, 227-268 (1938).
25. Uranova N, Orlovskaya D, Vikhreva O et al. Electron microscopy of oligodendroglia in severe mental illness. Brain Res. Bull. 55, 597-610 (2001). (Pubitemid 32888378)
26. Uranova N, Orlovskaya D. Ultrastructural pathology of neuronal connectivity in postmortem brains of schizophrenic patients. Ann. Psychiatr. 6, 55-72 (1996).
27. Uranova N, Casanova M, Devaughn N, Orlovskaya D, Denisov D. Ultrastructural alterations of synaptic contacts and astrocytes in postmortem caudate nucleus of schizophrenic patients (letter). Schizophr. Res. 22, 81-83 (1996).
28. Orlovskaya D, Vostrikov V, Rachmanova V, Uranova N. Decreased numerical density of oligodendroglial cells in post-mortem prefrontal cortex in schizophrenia, bipolar affective disorder, and major depression (abstr). Schizophr. Res. 41, 105-106 (2000).
29. Orlovskaya D, Denisov D, Uranova N. The ultrastructural pathology of myelinated fibers and oligodendroglial cells in autopsied caudate nucleus of schizophrenics. Schizophr. Res. 24, 39-40 (1997).
30. Orlovskaya D, Vikhreva O, Zimina I, Denisov D, Uranova N. Ultrastructural dystrophic changes of oligodendroglial cells in autopsied prefrontal cortex and striatum in schizophrenia: a morphometric study. Schizophr. Res. 36, 82-83 (1999).
31. Hof P, Haroutunian V, Friedrich VJ et al. Loss and altered spatial distrubition of oligodendrocytes in the superior frontal gyrus in schizophrenia. Biol. Psychiatry 53, 1075-1085 (2003 (Pubitemid 36695083)
32. Hof P, Haroutunian V, Copland C, Al E. Molecular and cellular evidence for an oligodendrocyte abnormality in schizophrenia. Neurochem. Res. 27, 1193-1200 (2002). (Pubitemid 35316115)
33. Kim S, Webster MJ. Integrative genome-wide association analysis of cytoarchitectural abnormalities in the prefrontal cortex of psychiatric disorders. Mol. Psychiatry 16(4), 452-461 (2010).
34. Kim S, Webster MJ. Correlation analysis between genome-wide expression profiles and cytoarchitectural abnormalities in the prefrontal cortex of psychiatric disorders. Mol. Psychiatry 15(3), 326-336 (2010).
35. Ewald H, Flint TJ, Jorgensen TH et al. Search for a shared segment on chromosome 10q26 in patients with bipolar affective disorder or schizophrenia from the Faroe Islands. Am. J. Med. Genet. 114(2), 196-204 (2002). (Pubitemid 34160472)
36. Farkas N, Lendeckel U, Dobrowolny H et al. Reduced density of ADAM 12-immunoreactive oligodendrocytes in the anterior cingulate white matter of patients with schizophrenia. World J. Biol. Psychiatry 11(3), 556-566 (2010).
37. Gregg JR, Herring NR, Naydenov AV, Hanlin RP, Konradi C. Downregulation of oligodendrocyte transcripts is associated with impaired prefrontal cortex function in rats. Schizophr. Res. 113(2-3), 277-287 (2009).
38. Mcdonald J, Althomsons S, Choi D, Goldberg M. Oligodendrocytes from forebrain are highly vulnerable to AMPA/kainate receptor mediated excitotoxicity. Nat. Med. 4, 291-297 (1998). (Pubitemid 28144086)
39. Farber N, Wozniak D, Price M, Al E. Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia? Biol. Psychiatry 38, 788-796 (1995). (Pubitemid 3020005)
40. Rees S, Inder T. Fetal and neonatal origins of altered brain development. Early Hum. Dev. 81, 753-761 (2005). (Pubitemid 41253520)
41. Bergles DE, Roberts JD, Somogyi P, Jahr CE. Glutamatergic synapses on oligodendrocyte precursor cells in the hippocampus. Nature 405(6783), 187-191 (2000). (Pubitemid 30313537)
42. Livni E, Munitz H, Tyano S et al. Further studies on cell-mediated immunity to myelin basic protein in schizophrenic patients. J. Neurol. Sci. 42, 437-440 (1979). (Pubitemid 9188022)
43. Kuritzky A, Livni E, Munitz H et al. Cell-mediated immunity to human myelin basic protein in schizophrenic patients. J. Neurol. Sci. 30, 369-373 (1976).
44. Rimon R, Ahokas A, Ruutianen J, Halonen P. Myelin basic protein antibodies in catatonic schizophrenia. J. Clin. Psychiatry 47, 26-28 (1986). (Pubitemid 16182755)
45. Schmitt A, Wilczek K, Blennow K et al. Altered thalamic membrane phospholipids in schizophrenia: a postmortem study. Biol. Psychiatry 56, 41-45 (2004). (Pubitemid 38813404)
46. Hennah W, Varilo T, Paunio T, Peltonen L. Haplotype analysis and identification of genes for a complex trait: examples from schizophrenia. Ann. Med. 36, 322-331 (2003). (Pubitemid 39233100)
47. Novak G, Kim D, Seeman P, Tallerico T. Schizophrenia and Nogo: elevated mRNA in cortex, and high prevalence of a homozygous CAA insert. Mol. Brain Res. 107, 183-189 (2002). (Pubitemid 35335536)
48. Covault J, Lee J, Jensen K, Kranzler H. Nogo 3′ untranslated region CAA insertion: failure to replicate association with schizophrenia and demonstration of marked population difference in the frequency of the insertion. Mol. Brain Res. 120, 197-200 (2004). (Pubitemid 38115818)
49. Xiong L, Rouleau G, Delisi L et al. CAA insertion polymorphism in the 3′UTR of Nogo gene on 2p14 is not associated with schizophrenia. Mol. Brain Res. 133, 153-156 (2005). (Pubitemid 40127500)
50. Gregorio S, Mury F, Ojopi E et al. Nogo CAA 3′UTR insertion polymorphism is not associated with schizophrenia nor with bipolar disorder. Schizophr. Res. 75, 5-9 (2005). (Pubitemid 40487968)
51. Tan E-C, Chong S-A, Wang H, Lim E-P, Teo Y-Y. Gender-specific association of insertion/deletion polymorphisms in the nogo gene and chronic schizophrenia. Mol. Brain Res. 139(2), 212-216 (2005). (Pubitemid 41317933)
52. Sinibaldi L, De Luca A, Bellacchio E et al. Mutations of the Nogo-66 receptor (RTN4R) gene in schizophrenia. Hum. Mutat. 24, 534-535 (2004).
53. Budel S, Padukkavidana T, Liu BP et al. Genetic variants of Nogo-66 receptor with possible association to schizophrenia block myelin inhibition of axon growth. J. Neurosci. 28(49), 13161-13172 (2008).
54. Hsu R, Woodroffe A, Lai WS et al. Nogo Receptor 1 (RTN4R) as a candidate gene for schizophrenia: analysis using human and mouse genetic approaches. PLoS One 2(11), e1234 (2007).
55. Willi R, Weinmann O, Winter C et al. Constitutive genetic deletion of the growth regulator Nogo-A induces schizophrenia-related endophenotypes. J. Neurosci. 30(2), 556-567 (2010).
56. Willi R, Aloy EM, Yee BK, Feldon J, Schwab ME. Behavioral characterization of mice lacking the neurite outgrowth inhibitor Nogo-A. Genes Brain Behav. 8(2), 181-192 (2009).
57. Wan C, Yang Y, Feng G et al. Polymorphisms of myelin-associated glycoprotein gene are associated with schizophrenia in the Chinese Han population. Neurosci. Lett. 388, 126-131 (2005). (Pubitemid 41208206)
58. Yang Y, Qin W, Shugart Y et al. Possible association of the MAG locus with schizophrenia in a Chinese Han cohort of family trios. Schizophr. Res. 75, 11-19 (2005). (Pubitemid 40487969)
59. Ross SE, Greenberg ME, Stiles CD. Basic helix-loop-helix factors in cortical development. Neuron 39(1), 13-25 (2003). (Pubitemid 36830945)
60. Sauvageot CM, Stiles CD. Molecular mechanisms controlling cortical gliogenesis. Curr. Opin. Neurobiol. 12(3), 244-249 (2002). (Pubitemid 34615748)
61. Georgieva L, Moskvina V, Peirce T et al. Convergent evidence that oligodendrocyte lineage transcription factor 2 (OLIG2) and interacting genes influence susceptibility to schizophrenia. Proc. Natl Acad. Sci. USA 103(33), 12469-12474 (2006). (Pubitemid 44267283)
62. Huang K, Tang W, Tang R et al. Positive association between OLIG2 and schizophrenia in the Chinese Han population. Hum. Genet. 122(6), 659-660 (2008).
63. Usui H, Takahashi N, Saito S et al. The 2′,3′-cyclic nucleotide 3′-phosphodiesterase and oligodendrocyte lineage transcription factor 2 genes do not appear to be associated with schizophrenia in the Japanese population. Schizophr. Res. 88(1-3), 245-250 (2006). (Pubitemid 44693254)
64. Qin W, Gao J, Xing Q et al. A family-based association study of PLP1 and schizophrenia. Neurosci. Lett. 375, 207-210 (2005). (Pubitemid 40202954)
65. Peirce TR, Bray NJ, Williams NM et al. Convergent evidence for 2′,3′-cyclic nucleotide 3′-phosphodiesterase as a possible susceptibility gene for schizophrenia. Arch. Gen. Psychiatry 63(1), 18-24 (2006). (Pubitemid 43040014)
66. Hakak Y, Walker J, Li C et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc. Natl Acad. Sci. USA 98, 4746-4751 (2001). (Pubitemid 32295047)
67. Copland C, Dracheva S, Davis K, Haroutunian V. mRNA expression of three isoforms of myelin associated glycoprotein (MAG) in patients with schizophrenia [abstract]. Abstr. Soc. Neurosci. 28, 494 (2002).
68. Tkachev D, Mimmack M, Ryan M et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 362, 798-805 (2003). (Pubitemid 37093922)
69. Sugai T, Kawamura M, Iritani S et al. Prefrontal abnormality of schizophrenia revealed by DNA microarray: impact on glial and neurotrophic gene expression. Ann. NY Acad. Sci. 1025, 84-91 (2004). (Pubitemid 39643849)
70. Paulson L, Martin P, Persson A, Al E. Comparative genome- and proteome analysis of cerebral cortex from MK-801- treated rats. J. Neurosci. Res. 15, 526-533 (2003). (Pubitemid 36158336)
71. Mitkus SN, Hyde TM, Vakkalanka R et al. Expression of oligodendrocyte-associated genes in dorsolateral prefrontal cortex of patients with schizophrenia. Schizophr. Res. 98(1-3), 129-138 (2008). (Pubitemid 350245594)
72. Aston C, Jiang L, Sokolov B. Microarray analysis of postmortem temporal cortex from patients with schizophrenia. J. Neurosci. Res. 77, 858-866 (2004). (Pubitemid 39187068)
73. Katsel P, Davis K, Haroutunian V. Variations in myelin and oligodendrocyte-related gene expression across multiple brain regions in schizophrenia: a gene ontology study. Schizophr. Res. 79(2-3), 157-173 (2005). (Pubitemid 41457256)
74. Paez P, Marta C, Moreno M, Soto E, Pasquini J. Apotransferrin decreases migration and enhances differentiation of oligodendroglial progenitor cells in an in-vitro system. Dev. Neurosci. 24, 47-58 (2002). (Pubitemid 36151217)
75. Woo T, Crowell A. Targeting synapses and myelin in the prevention of schizophrenia. Schizophr. Res. 73, 193-207 (2005). (Pubitemid 40093880)
76. Mccullumsmith RE, Gupta D, Beneyto M et al. Expression of transcripts for myelination-related genes in the anterior cingulate cortex in schizophrenia. Schizophr. Res. 90(1-3), 15-27 (2007). (Pubitemid 46177577)
77. Dracheva S, Davis K, Chin B, Woo D, Schmeidler J, Haroutunian V. Myelin-associated mRNA and protein expression deficits in the anterior cingulate cortex and hippocampus in elderly schizophrenia patients. Neurol. Dis. 21(3), 531-540 (2005).
78. Byne W, Dracheva S, Chin B, Schmeidler JM, Davis KL, Haroutunian V. Schizophrenia and sex associated differences in the expression of neuronal and oligodendrocyte-specific genes in individual thalamic nuclei. Schizophr. Res. 98(1-3), 118-128 (2008). (Pubitemid 350235902)
79. Haroutunian V, Katsel P, Dracheva S, Stewart DG, Davis KL. Variations in oligodendrocyte-related gene expression across multiple cortical regions: implications for the pathophysiology of schizophrenia. Int. J. Neuropsychopharmacol. 10(4), 565-573 (2007). (Pubitemid 46985258)
80. Parlapani E, Schmitt A, Erdmann A et al. Association between myelin basic protein expression and left entorhinal cortex pre-a cell layer disorganization in schizophrenia. Brain Res. 1301, 126-134 (2009).
81. Novak G, Tallerico T. Nogo A, B and C expression in schizophrenia, depression and bipolar frontal cortex, and correlation of Nogo expression with CAA/TATC polymorphism in 3′-UTR. Brain Res. 1120(1), 161-171 (2006). (Pubitemid 44649294)
82. Haroutunian V, Katsel P, Dracheva S, Davis KL. The human homolog of the QKI gene affected in the severe dysmyelination quaking mouse phenotype: downregulated in multiple brain regions in schizophrenia. Am. J. Psychiatry 163(10), 1834-1837 (2006). (Pubitemid 44522497)
83. Katsel P, Davis KL, Li C et al. Abnormal indices of cell cycle activity in schizophrenia and their potential association with oligodendrocytes. Neuropsychopharmacology 33(12), 2993-3009 (2008).
84. Aberg K, Saetre P, Jareborg N, Jazin E. Human QKI, a potential regulator of mRNA expression of human oligodendrocyte-related genes involved in schizophrenia. Proc. Natl Acad. Sci. USA 103(19), 7482-7487 (2006). (Pubitemid 43727859)
85. Fatemi SH, Folsom TD, Reutiman TJ et al. Abnormal expression of myelination genes and alterations in white matter fractional anisotropy following prenatal viral influenza infection at E16 in mice. Schizophr. Res. 112(1-3), 46-53 (2009).
86. Fatemi S, Reutiman T, Folsom T et al. Maternal infection leads to abnormal gene regulation and brain atrophy in mouse offspring: implications for genesis of neurodevelopmental disorders. Schizophr. Res. 99, 56-70 (2008).
87. Harris LW, Lockstone HE, Khaitovich P, Weickert CS, Webster MJ, Bahn S. Gene expression in the prefrontal cortex during adolescence: implications for the onset of schizophrenia. BMC Med. Genomics 2, 28 (2009).
88. Sokolov BP. Oligodendroglial abnormalities in schizophrenia, mood disorders and substance abuse. Comorbidity, shared traits, or molecular phenocopies? Int. J. Neuropsychopharmacol. 10(4), 547-555 (2007). (Pubitemid 46985259)
89. Wright I, Rabe-Hesketh S, Woodruff P, David A, Murray R, Bullmore E. Meta-analysis of regional brain volumes in schizophrenia. Am. J. Psychiatry 157, 16-25 (2000). (Pubitemid 30027416)
90. Cannon T, Van Erp T, Huttunen M et al. Regional gray matter, white matter, and cerebrospinal fluid distributions in schizophrenic patients, their siblings, and controls. Arch. Gen. Psychiatry 55, 1084-1091 (1998). (Pubitemid 28558280)
91. Hulshoff Pol H, Brans R, Van Haren N et al. Gray and white matter volume abnormalities in monozygotic and same-gender dizygotic twins discordant for schizophrenia. Biol. Psychiatry 55, 126-130 (2004). (Pubitemid 38367715)
92. Bose SK, Mackinnon T, Mehta MA et al. The effect of ageing on grey and white matter reductions in schizophrenia. Schizophr. Res. 112(1-3), 7-13 (2009).
93. Tanskanen P, Haapea M, Veijola J et al. Volumes of brain, grey and white matter and cerebrospinal fluid in schizophrenia in the Northern Finland 1966 Birth Cohort: an epidemiological approach to analysis. Psychiatry Res. 174(2), 116-120 (2009).
94. Buchanan R, Vladar K, Barta P, Pearlson G. Structural evaluation of the prefrontal cortex in schizophrenia. Am. J. Psychiatry 155, 1049-1055 (1998). (Pubitemid 28357730)
95. Sanfilipo M, Lafargue T, Rusinek H et al. Volumetric measure of the frontal and temporal lobe regions in schizophrenia: relationship to negative symptoms. Arch. Gen. Psychiatr. 57, 471-480 (2000). (Pubitemid 30257261)
96. Sigmundsson T, Suckling J, Maier M, Al E. Structural abnormalities in frontal, temporal and limbic regions and interconnecting white matter tracts in schizophrenic patients with prominent negative symptoms. Am. J. Psychiatry 158, 234-243 (2001). (Pubitemid 32116521)
97. Breir A, Buchanan R, Elkashef A, Munson R, Kirkpatrick B, Gellad F. Brain morphology and schizophrenia: a magnetic resonance imaging study of limbic, prefrontal cortex, and caudate structures. Arch. Gen. Psychiatr. 49, 921-926 (1992).
98. Hulshoff Pol H, Schnack H, Bertens M et al. Volume changes in gray matter in patients with schizophrenia. Am. J. Psychiatry 159, 244-250 (2002). (Pubitemid 34126901)
99. Wible C, Anderson J, Shenton M et al. Prefrontal cortex, negative symptoms, and schizophrenia: an MRI study. Psychiatr. Res. 108, 65-78 (2001 (Pubitemid 34003569)
100. Paillere-Martinot M, Caclin A, Artiges E et al. Cerebral gray and white matter reductions and clinical correlates in patients with early onset schizophrenia. Schizophr. Res. 50, 19-26 (2001). (Pubitemid 32510884)
101. Mathalon D, Pfefferbaum A, Lim K, Rosenbloom M, Sullivan E. Compounded brain volume deficits in schizophrenia-alcoholism morbidity. Arch. Gen. Psychiatry 60, 245-252 (2003). (Pubitemid 36307435)
102. Ho B, Andreasen N, Nopoulos P, Arndt S, Magnotta V, Flaum M. Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. Arch. Gen. Psychiatry 60, 585-594 (2003). (Pubitemid 36682316)
103. Arango C, Breier A, Mcmahon R, Carpenter W, Buchanan R. The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal and caudate brain volumes. Am. J. Psychiatry 160, 1421-1427 (2003). (Pubitemid 41070916)
104. Okugawa G, Sedvallo G, Agartz I. Reduced grey and white matter volumes in the temporal lobe of male patients with chronic schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 252, 120-123 (2002). (Pubitemid 36062417)
105. Takahashi K, Suzuki M, Kawasaki Y, Al E. Perigenual cingulate gyrus volume in patients with schizophrenia: a magnetic resonance imaging study. Biol. Psychiatry 53, 593-600 (2003). (Pubitemid 36385061)
106. Mitelman S, Shihabuddin L, Brickman A, Hazlett E, Buchsbaum M. MRI assessment of gray and white matter distribution in Brodmanns areas of the cortex in pattients with schizophrenia with good and poor outcomes. Am. J. Psychiatry 160, 2154-2168 (2003). (Pubitemid 39619609)
107. Davies D, Wardell A, Woolsey R, James A. Enlargement of the fornix in early onset schizophrenia: a quantitative MRI study. Neurosci. Lett. 301, 163-166 (2001). (Pubitemid 32226425)
108. Nieuwenhuys R, Voogd J, Van Huijzen C. The Human Central Nervous System. Springer-Verlag, Berlin, Germany (1988).
109. Zhou S, Suzuki M, Hagino H et al. Decreased volume and increased asymmetry of the anterior limb of the internal capsule in patients with schizophrenia. Biol. Psychiatry 54(4), 427-436 (2003). (Pubitemid 37289449)
110. Goghari VM, Lang DJ, Khorram B et al. Anterior internal capsule volumes increase in patients with schizophrenia switched from typical antipsychotics to olanzapine. J. Psychopharmacol. 25(5), 621-629 (2010).
111. Lang DJ, Khorram B, Goghari VM et al. Reduced anterior internal capsule and thalamic volumes in first-episode psychosis. Schizophr. Res. 87(1-3), 89-99 (2006). (Pubitemid 44428117)
112. Brickman AM, Buchsbaum MS, Ivanov Z et al. Internal capsule size in good-outcome and poor-outcome schizophrenia. J. Neuropsychiatry Clin. Neurosci. 18(3), 364-376 (2006).
113. Wobrock T, Gruber O, Schneider-Axmann T et al. Internal capsule size associated with outcome in first-episode schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 259(5), 278-283 (2009).
114. Dequardo J, Keshavan M, Bookstein F, Al E. Landmark-based morphometric analysis of first-episode schizophrenia. Biol. Psychiatry 45, 1321-1328 (1999). (Pubitemid 29292509)
115. Downhill J, Buchsbaum M, Wei T, Al E. Shape and size of the corpus callosum in schizophrenia and schizotypal personality disorder. Schizophr. Res. 42, 193-208 (2000). (Pubitemid 30216531)
116. Frumin M, Golland P, Kikinis R et al. Shape differences in the corpus callosum in first-episode schizophrenia and first-episode psychotic affective disorder. Am. J. Psychiatry 159, 866-868 (2002). (Pubitemid 34465066)
117. Narr KL, Thompson PM, Sharma T, Moussai J, Cannestra AF, Toga AW. Mapping morphology of the corpus callosum in schizophrenia. Cereb. Cortex 10(1), 40-49 (2000). (Pubitemid 30022831)
118. Mitelman SA, Nikiforova YK, Canfield EL et al. A longitudinal study of the corpus callosum in chronic schizophrenia. Schizophr. Res. 114(1-3), 144-153 (2009).
119. Narr KL, Cannon TD, Woods RP et al. Genetic contributions to altered callosal morphology in schizophrenia. J. Neurosci. 22(9), 3720-3729 (2002). (Pubitemid 37465777)
120. Walterfang M, Wood AG, Reutens DC et al. Morphology of the corpus callosum at different stages of schizophrenia: cross-sectional study in first-episode and chronic illness. Br. J. Psychiatry 192(6), 429-434 (2008). (Pubitemid 351809895)
121. Arnone D, Mcintosh A, Tan G, Ebmeier K. Meta-analysis of magnetic resonance imaging studies of the corpus callosum in schizophrenia. Schizophr. Res. 101, 124-132 (2008).
122. Rotarska-Jagiela A, Schonmeyer R, Oertel V, Haenschel C, Vogeley K, Linden DE. The corpus callosum in schizophrenia-volume and connectivity changes affect specific regions. Neuroimage 39(4), 1522-1532 (2008).
123. Seok JH, Park HJ, Chun JW et al. White matter abnormalities associated with auditory hallucinations in schizophrenia: a combined study of voxel-based analyses of diffusion tensor imaging and structural magnetic resonance imaging. Psychiatry Res. 156(2), 93-104 (2007).
124. Wolf RC, Hose A, Frasch K, Walter H, Vasic N. Volumetric abnormalities associated with cognitive deficits in patients with schizophrenia. Eur. Psychiatry 23(8), 541-548 (2008).
125. Diwadkar V, Dabellis M, Sweeney J, Pettegrew J, Keshavan M. Abnormalities in MRI-measured signal intensity in the corpus callosum in schizophrenia. Schizophr. Res. 67, 277-282 (2004). (Pubitemid 38251459)
126. Bachmann S, Pantel J, Flender A, Bottmer C, Essig M, Schroder J. Corpus callosum in first-episode patients with schizophrenia - a magnetic resonance imaging study. Psychol. Med. 33, 1019-1027 (2003). (Pubitemid 37009820)
127. Keshavan M, Diwadkar V, Harenski K, Al E. Abnormalities of the corpus callosum in first episode treatment naive schizophrenia. J. Neurol. Neurosurg. Psychiatr. 72, 757-760 (2002). (Pubitemid 34557020)
128. Walterfang M, Wood AG, Barton S et al. Corpus callosum size and shape alterations in individuals with bipolar disorder and their first-degree relatives. Prog. Neuropsychopharmacol. Biol. Psychiatry 33(6), 1050-1057 (2009).
129. Walterfang M, Wood AG, Reutens DC et al. Corpus callosum size and shape in first-episode affective and schizophrenia-spectrum psychosis. Psychiatry Res. 173(1), 77-82 (2009).
130. Walterfang M, Yung A, Wood AG et al. Corpus callosum shape alterations in individuals prior to the onset of psychosis. Schizophr. Res. 103(1-3), 1-10 (2008).
131. Woodruff P, Mcmanus I, David A. Meta-analysis of corpus callosum size in schizophrenia. J. Neurol. Neurosurg. Psychiatr. 58, 457-461 (1995).
132. Meisenzahl E, Frodl T, Greiner J et al. Corpus callosum size in schizophrenia - a magnetic resonance imaging analysis. Eur. Arch. Psychiatry Clin. Neurosci. 249, 305-312 (1999). (Pubitemid 30011733)
133. Pagsberg AK, Baare WF, Raabjerg Christensen AM et al. Structural brain abnormalities in early onset first-episode psychosis. J. Neural. Transm. 114(4), 489-498 (2007 (Pubitemid 46474864)
134. Price G, Cercignani M, Bagary MS et al. A volumetric MRI and magnetization transfer imaging follow-up study of patients with first-episode schizophrenia. Schizophr. Res. 87(1-3), 100-108 (2006). (Pubitemid 44428132)
135. Spalletta G, Tomaiuolo F, Marino V, Bonaviri G, Trequattrini A, Caltagirone C. Chronic schizophrenia as a brain misconnection syndrome: a white matter voxel-based morphometry study. Schizophr. Res. 64, 15-23 (2003). (Pubitemid 37153345)
136. Whitford TJ, Grieve SM, Farrow TF et al. Volumetric white matter abnormalities in first-episode schizophrenia: a longitudinal, tensor-based morphometry study. Am. J. Psychiatry 164(7), 1082-1089 (2007). (Pubitemid 47121397)
137. Hulshoff Pol H, Schnack H, Mandl R et al. Focal white matter density changes in schizophrenia: reduced inter-hemispheric connectivity. Neuroimage 21, 27-35 (2004). (Pubitemid 38114993)
138. Mcintosh A, Job D, Moorhead T, Harrison L, Lawrie S, Johnstone E. White matter density in patients with schizophrenia, bipolar disorder and their unaffected relatives. Biol. Psychiatry 58(3), 254-257 (2005). (Pubitemid 41112275)
139. Antonova E, Kumari V, Morris R, Halari R, Mehrotra R, Sharma T. The relationship of structural alterations to cognitive deficits in schizophrenia: a voxel-based morphometry study. Biol. Psychiatry 58, 457-467 (2005). (Pubitemid 41393608)
140. Walterfang M, Mcguire P, Yung A et al. White matter volume changes in people who develop psychosis. Br. J. Psychiatry 193, 210-215 (2008).
141. Chan WY, Yang GL, Chia MY et al. White matter abnormalities in first-episode schizophrenia: a combined structural MRI and DTI study. Schizophr. Res. 119(1-3), 52-60 (2010).
142. Chua SE, Cheung C, Cheung V et al. Cerebral grey, white matter and CSF in never-medicated, first-episode schizophrenia. Schizophr. Res. 89(1-3), 12-21 (2007). (Pubitemid 44895585)
143. Tanskanen P, Ridler K, Murray GK et al. Morphometric brain abnormalities in schizophrenia in a population-based sample: relationship to duration of Illness. Schizophr. Bull. 36(4), 766-77 (2008).
144. Witthaus H, Brune M, Kaufmann C et al. White matter abnormalities in subjects at ultra high-risk for schizophrenia and fepisode schizophrenic patients. Schizophr. Res. 102(1-3), 141-149 (2008).
145. Wible C, Shenton M, Hokama H et al. Prefrontal cortex and schizophrenia: a quantitative magnetic resonance imaging study. Arch. Gen. Psychiatr. 52, 279-288 (1995).
146. Di X, Chan RC, Gong QY. White matter reduction in patients with schizophrenia as revealed by voxel-based morphometry: an activation likelihood estimation meta-analysis. Prog. Neuropsychopharmacol. Biol. Psychiatry 33(8), 1390-1394 (2009).
147. Dousset V, Grossman R, Ramer K et al. Experimental allergic encephalomyelitis and multiple sclerosis: lesion characterization with magnetization transfer imaging. Radiology 182, 483-491 (1992).
148. Dousset V, Brochet B, Vital A et al. Lysolecithin-induced demyelination in primates: preliminary in vivo study with MR and magnetization transfer. Am. J. Neuroradiol. 16, 225-231 (1995).
149. Van Waesberghe J, Kamphorst W, De Groot C et al. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann. Neurol. 46(5), 747-754 (1999). (Pubitemid 29518136)
150. Foong J, Maier M, Barker G, Brocklehurs S, Miller D, Ron M. In vivo investigation of white matter pathology in schizophrenia with magnetisation transfer imaging. J. Neurol. Neurosurg. Psychiatr. 68, 70-74 (2000). (Pubitemid 30248662)
151. Foong J, Symms M, Barker G, Al E. Neuropathological abnormalities in schizophrenia: evidence from magnetization transfer imaging. Brain 124, 882-892 (2001). (Pubitemid 32458501)
152. Bagary M, Symms M, Barker G, Mutsatsa S, Joyce E, Ron M. Gray and white matter brain abnormalities in first-episode schizophrenia inferred from magnetization transfer imaging. Arch. Gen. Psychiatry 60, 779-788 (2003). (Pubitemid 36960909)
153. Price G, Cercignani M, Chu EM et al. Brain pathology in first-episode psychosis: magnetization transfer imaging provides additional information to MRI measurements of volume loss. Neuroimage 49(1), 185-192 (2010).
154. Kubicki M, Park H, Westin C et al. DTI and MTR abnormalities in schizophrenia: analysis of white matter integrity. Neuroimage 26, 1109-1118 (2005). (Pubitemid 40806489)
155. Mandl RC, Schnack HG, Luigjes J et al. Tract-based analysis of magnetization transfer ratio and diffusion tensor imaging of the frontal and frontotemporal connections in schizophrenia. Schizophr. Bull. 36(4), 778-787 (2008).
156. Lim K, Hedehus M, Moseley M, De Crespigny A, Sullivan E, Pfefferbaum A. Compromised white matter integrity in schizophrenia inferred from diffusion tensor imaging. Arch. Gen. Psychiatr. 56, 367-374 (1999). (Pubitemid 29165183)
157. Steel R, Bastin M, Mcconnell S et al. Diffusion tensor imaging (DTI) and proton magnetic resonance spectroscopy (MRS) in schizophrenic subjects and normal controls. Psychiatr. Res. 106, 161-170 (2001). (Pubitemid 32520942)
158. Hoptman M, Volavka J, Johnson G, Weiss E, Bilder R, Lim K. Frontal white matter microstructure, aggression, and impulsivity in men with schizophrenia: a preliminary study. Biol. Psychiatry 52, 9-14 (2002). (Pubitemid 34655551)
159. Wolkin A, Choi C, Szilagyi S, Sanfilipo M, Rotrosen J, Lim K. Inferior frontal white matter anisotropy and negative symptoms of schizophrenia: a diffusion tensor imaging study. Am. J. Psychiatry 160, 572-574 (2003). (Pubitemid 41094269)
160. Minami T, Nobuhara K, Okugawa G, Al E. Diffusion tensor magnetic resonance imaging ot disruption of regional white matter in schizophrenia. Neuropsychobiol. 47, 141-145 (2003). (Pubitemid 36676977)
161. Sun Z, Wang F, Cui L et al. Abnormal anterior cingulum in patients with schizophrenia: a diffusion tensor imaging study. Neuroreport 14, 1833-1836 (2003). (Pubitemid 37372613)
162. Kumra S, Ashtari M, Mcmeniman M et al. Reduced frontal white matter integrity in early-onset schizophrenia: a preliminary study. Biol. Psychiatry 55, 1138-1145 (2004). (Pubitemid 38739447)
163. Kitamura H, Matsuzawa H, Shiori T, Someya T, Kwee I, Nakada T. Diffusion tensor analysis in chronic schizophrenia: a preliminary study on a high-field (3.0T) system. Eur. Arch. Psychiatry Clin. Neurosci. 255(5), 313-318 (2005). (Pubitemid 41618803)
164. Shin YW, Kwon JS, Ha TH et al. Increased water diffusivity in the frontal and temporal cortices of schizophrenic patients. Neuroimage 30(4), 1285-1291 (2006).
165. Rose SE, Chalk JB, Janke AL et al. Evidence of altered prefrontal-thalamic circuitry in schizophrenia: an optimized diffusion MRI study. Neuroimage 32(1), 16-22 (2006).
166. Kuroki N, Kubicki M, Nestor PG et al. Fornix integrity and hippocampal volume in male schizophrenic patients. Biol. Psychiatry 60(1), 22-31 (2006 (Pubitemid 43949145)
167. Fitzsimmons J, Kubicki M, Smith K et al. Diffusion tractography of the fornix in schizophrenia. Schizophr. Res. 107(1), 39-46 (2009).
168. Foong J, Maier M, Clark C, Barker G, Miller D, Ron M. Neuropathological abnormalities of the corpus callosum in schizophrenia: a diffusion tensor imaging study. J. Neurol. Neurosurg. Psychiatr. 68, 242-244 (2000). (Pubitemid 30245855)
169. Price G, Bagary M, Cercignani M, Altmann D, Ron M. The corpus callosum in first episode schizophrenia: a diffusion tensor imaging study. J. Neurol. Neurosurg. Psychiatr. 76(2005).
170. Brambilla P, Cerini R, Gasparini A et al. Investigation of corpus callosum in schizophrenia with diffusion imaging. Schizophr. Res. 79(2-3), 201-210 (2005). (Pubitemid 41457260)
171. Kanaan RA, Shergill SS, Barker GJ et al. Tract-specific anisotropy measurements in diffusion tensor imaging. Psychiatry Res. 146(1), 73-82 (2006). (Pubitemid 43269991)
172. Kubicki M, Westin C, Nestor P et al. Cingulate fasciculus integrity disruption in schizophrenia: a magnetic resonance diffusion tensor imaging study. Biol. Psychiatry 54, 1171-1180 (2003). (Pubitemid 37474111)
173. Wang F, Sun Z, Cui L et al. Anterior cingulum abnormalities in male patients with schizophrenia determined through diffusion tensor imaging. Am. J. Psychiatry 161, 573-575 (2004). (Pubitemid 38326117)
174. Nestor P, Kubicki M, Gurrera R et al. Neuropsychological correlates of diffusion tensor imaging in schizophrenia. Neuropsychology 18, 629-637 (2004). (Pubitemid 39363148)
175. Jones D, Catani M, Pierpaoli C et al. Age effects on diffusion tensor magnetic resonance imaging tractography measures of frontal cortex connections in schizophrenia. Hum. Brain Mapp. 27(3), 230-238 (2005).
176. Takei K, Yamasue H, Abe O et al. Structural disruption of the dorsal cingulum bundle is associated with impaired Stroop performance in patients with schizophrenia. Schizophr. Res. 114(1-3), 119-127 (2009).
177. Voineskos AN, Lobaugh NJ, Bouix S et al. Diffusion tensor tractography findings in schizophrenia across the adult lifespan. Brain 133(Pt 5), 1494-1504 (2010).
178. Wang F, Sun Z, Du X et al. A diffusion tensor imaging study of middle and superior cerebellar peduncle in male patients with schizophrenia. Neurosci. Lett. 348, 135-138 (2003). (Pubitemid 36976824)
179. Okugawa G, Nobuhara K, Minami T et al. Subtle disruption of the middle cerebellar peduncles in patients with schizophrenia. Neuropsychobiol. 50, 119-123 (2004). (Pubitemid 39077829)
180. Okugawa G, Nobuhara K, Sugimoto T, Kinoshita T. Diffusion tensor imaging study of the middle cerebellar peduncle in patients with schizophrenia. Cerebellum 4, 123-127 (2005). (Pubitemid 40943009)
181. Okugawa G, Nobuhara K, Minami T et al. Neural disorganization in the superior cerebellar peduncle and cognitive abnormality in patients with schizophrenia: a diffusion tensor imaging study. Prog. Neuropsychopharmacol. Biol. Psychiatry 30(8), 1408-1412 (2006). (Pubitemid 44634945)
182. Hubl D, Koenig T, Strik W et al. Pathways that make voices: white matter changes in auditory hallucinations. Arch. Gen. Psychiatr. 61, 658-668 (2004). (Pubitemid 38890798)
183. Kubicki M, Westin C, Maier S et al. Uncinate fasciculus findings in schizophrenia: a magnetic resonance diffusion tensor imaging study. Am. J. Psychiatry 159, 813-820 (2002). (Pubitemid 34465056)
184. Jones DK, Catani M, Pierpaoli C et al. Age effects on diffusion tensor magnetic resonance imaging tractography measures of frontal cortex connections in schizophrenia. Hum. Brain Mapp. 27(3), 230-238 (2006).
185. Karlsgodt KH, Van Erp TG, Poldrack RA, Bearden CE, Nuechterlein KH, Cannon TD. Diffusion tensor imaging of the superior longitudinal fasciculus and working memory in recent-onset schizophrenia. Biol. Psychiatry 63(5), 512-518 (2008). (Pubitemid 351220789)
186. Buchsbaum MS, Schoenknecht P, Torosjan Y et al. Diffusion tensor imaging of frontal lobe white matter tracts in schizophrenia. Ann. Gen. Psychiatry 5, 19 (2006).
187. Schlosser RG, Nenadic I, Wagner G et al. White matter abnormalities and brain activation in schizophrenia: a combined DTI and fMRI study. Schizophr. Res. 89(1-3), 1-11 (2007). (Pubitemid 44881306)
188. Mitelman SA, Newmark RE, Torosjan Y et al. White matter fractional anisotropy and outcome in schizophrenia. Schizophr. Res. 87(1-3), 138-159 (2006). (Pubitemid 44428130)
189. Agartz I, Andersson J, Skare S. Abnormal brain white matter in schizophrenia: a diffusion tensor imaging study. Neuroreport 12, 2251-2254 (2001). (Pubitemid 32646282)
190. Ardekani B, Nierenberg J, Hoptman M, Javitt D, Lim K. MRI study of white matter diffusion anisotropy in schizophrenia. Neuroreport 14, 2025-2029 (2003).
191. Caan MW, Vermeer KA, Van Vliet LJ et al. Shaving diffusion tensor images in discriminant analysis: a study into schizophrenia. Med. Image Anal. 10(6), 841-849 (2006). (Pubitemid 44804131)
192. Mori T, Ohnishi T, Hashimoto R et al. Progressive changes of white matter integrity in schizophrenia revealed by diffusion tensor imaging. Psychiatry Res. 154(2), 133-145 (2007).
193. Nestor PG, Kubicki M, Gurrera RJ et al. Neuropsychological correlates of diffusion tensor imaging in schizophrenia. Neuropsychology 18(4), 629-637 (2004). (Pubitemid 39363148)
194. Shergill SS, Kanaan RA, Chitnis XA et al. A diffusion tensor imaging study of fasciculi in schizophrenia. Am. J. Psychiatry 164(3), 467-473 (2007). (Pubitemid 46513161)
195. Hao Y, Liu Z, Jiang T et al. White matter integrity of the whole brain is disrupted in first-episode schizophrenia. Neuroreport 17(1), 23-26 (2006). (Pubitemid 43005734)
196. Fujiwara H, Namiki C, Hirao K et al. Anterior and posterior cingulum abnormalities and their association with psychopathology in schizophrenia: a diffusion tensor imaging study. Schizophr. Res. 95(1-3), 215-222 (2007). (Pubitemid 47313639)
197. Seal ML, Yucel M, Fornito A et al. Abnormal white matter microstructure in schizophrenia: a voxelwise analysis of axial and radial diffusivity. Schizophr. Res. 101(1-3), 106-110 (2008).
198. Burns J, Job D, Bastin M et al. Structural disconnectivity in schizophrenia: a diffusion tensor magnetic resonance imaging study. Br. J. Psychiatry 182, 439-443 (2003). (Pubitemid 36560981)
199. Hoptman M, Ardekani B, Butler P, Nierenberg J, Javitt D, Lim K. DTI and impulsivity in schizophrenia: a first voxelwise correlational analysis. Neuroreport 15, 2467-2470 (2004). (Pubitemid 39579334)
200. Perez-Iglesias R, Tordesillas-Gutierrez D, Mcguire PK et al. White matter integrity and cognitive impairment in first-episode psychosis. Am. J. Psychiatry 167(4), 451-458 (2010).
201. Skelly LR, Calhoun V, Meda SA, Kim J, Mathalon DH, Pearlson GD. Diffusion tensor imaging in schizophrenia: relationship to symptoms. Schizophr. Res. 98(1-3), 157-162 (2008). (Pubitemid 350235907)
202. Szeszko PR, Ardekani BA, Ashtari M et al. White matter abnormalities in first-episode schizophrenia or schizoaffective disorder: a diffusion tensor imaging study. Am. J. Psychiatry 162(3), 602-605 (2005 (Pubitemid 40343930)
203. Kyriakopoulos M, Frangou S. Recent diffusion tensor imaging findings in early stages of schizophrenia. Curr. Opin. Psychiatry 22(2), 168-176 (2009).
204. Perez-Iglesias R, Tordesillas-Gutierrez D, Barker GJ et al. White matter defects in first episode psychosis patients: a voxelwise analysis of diffusion tensor imaging. Neuroimage 49(1), 199-204 (2010).
205. Karlsgodt KH, Niendam TA, Bearden CE, Cannon TD. White matter integrity and prediction of social and role functioning in subjects at ultra-high risk for psychosis. Biol. Psychiatry 66(6), 562-569 (2009).
206. Munoz Maniega S, Lymer GK, Bastin ME et al. A diffusion tensor MRI study of white matter integrity in subjects at high genetic risk of schizophrenia. Schizophr. Res. 106(2-3), 132-139 (2008).
207. Hoptman MJ, Nierenberg J, Bertisch HC et al. A DTI study of white matter microstructure in individuals at high genetic risk for schizophrenia. Schizophr. Res. 106(2-3), 115-124 (2008).
208. Ellison-Wright I, Bullmore E. Meta-analysis of diffusion tensor imaging studies in schizophrenia. Schizophr. Res. 108(1-3), 3-10 (2009).
209. Jeong B, Wible CG, Hashimoto R, Kubicki M. Functional and anatomical connectivity abnormalities in left inferior frontal gyrus in schizophrenia. Hum. Brain Mapp. 30(12), 4138-4151 (2009).
210. Gusnard DA, Akbudak E, Shulman GL, Raichle ME. Medial prefrontal cortex and self-referential mental activity: relation to a default mode of brain function. Proc. Natl Acad. Sci. USA 98(7), 4259-4264 (2001). (Pubitemid 32249932)
211. Raichle ME, Macleod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL. A default mode of brain function. Proc. Natl Acad. Sci. USA 98(2), 676-682 (2001). (Pubitemid 32105102)
212. Skudlarski P, Jagannathan K, Calhoun VD, Hampson M, Skudlarska BA, Pearlson G. Measuring brain connectivity: diffusion tensor imaging validates resting state temporal correlations. Neuroimage 43(3), 554-561 (2008).
213. Greicius MD, Supekar K, Menon V, Dougherty RF. Resting-state functional connectivity reflects structural connectivity in the default mode network. Cereb. Cortex 19(1), 72-78 (2009).
214. Teipel SJ, Bokde AL, Meindl T et al. White matter microstructure underlying default mode network connectivity in the human brain. Neuroimage 49(3), 2021-2032 (2010).
215. Skudlarski P, Jagannathan K, Anderson K et al. Brain connectivity is not only lower but different in schizophrenia: a combined anatomical and functional approach. Biol. Psychiatry 68(1), 61-69 (2010).
216. Whitford TJ, Ford JM, Mathalon DH, Kubicki M, Shenton ME. Schizophrenia, myelination, and delayed corollary discharges: a hypothesis. Schizophr. Bull. DOI: 10.1093/schbul/sbq105 (2010) (Epub ahead of print).
217. Whitford TJ, Mathalon DH, Shenton ME et al. Electrophysiological and diffusion tensor imaging evidence of delayed corollary discharges in patients with schizophrenia. Psychol. Med. 41(5), 959-969 (2011).
218. Feinberg I. Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence? J. Psychiatr. Res. 17(4), 319-334 (1982). (Pubitemid 14249821)
219. Stephan KE, Baldeweg T, Friston KJ. Synaptic plasticity and dysconnection in schizophrenia. Biol. Psychiatry 59(10), 929-939 (2006). (Pubitemid 44288017)
220. Stephan KE, Friston KJ, Frith CD. Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring. Schizophr. Bull. 35(3), 509-527 (2009).
221. Feinberg I. Efference copy and corollary discharge: implications for thinking and its disorders. Schizophr. Bull. 4(4), 636-640 (1978). (Pubitemid 9085832)
222. Frith C. The Cognitive Neuropsychology of Schizophrenia. Lawrence Erlbaum Associates, Hove, UK (1992).
223. Smieskova R, Fusar-Poli P, Allen P et al. The effects of antipsychotics on the brain: what have we learnt from structural imaging of schizophrenia? - A systematic review. Curr. Pharm. Des. 15(22), 2535-2549 (2009).
224. Vita A, De Peri L. The effects of antipsychotic treatment on cerebral structure and function in schizophrenia. Int. Rev. Psychiatry 19(4), 429-436 (2007).
225. Lieberman JA, Tollefson GD, Charles C et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch. Gen. Psychiatry 62(4), 361-370 (2005). (Pubitemid 40471685)
226. Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch. Gen. Psychiatry 68(2), 128-137 (2011).
227. Dorph-Petersen KA, Pierri JN, Perel JM, Sun Z, Sampson AR, Lewis DA. The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology 30(9), 1649-1661 (2005). (Pubitemid 43086022)
228. Wang HD, Dunnavant FD, Jarman T, Deutch AY. Effects of antipsychotic drugs on neurogenesis in the forebrain of the adult rat. Neuropsychopharmacology 29(7), 1230-1238 (2004). (Pubitemid 38780646)
229. Niu J, Mei F, Li N et al. Haloperidol promotes proliferation but inhibits differentiation in rat oligodendrocyte progenitor cell cultures. Biochem. Cell. Biol. 88(4), 611-620 (2010).
230. Wang H, Xu H, Niu J et al. Haloperidol activates quiescent oligodendroglia precursor cells in the adult mouse brain. Schizophr. Res. 119(1-3), 164-174 (2010).
231. Zhang Y, Xu H, Jiang W et al. Quetiapine alleviates the cuprizone-induced white matter pathology in the brain of C57BL/6 mouse. Schizophr. Res. 106(2-3), 182-191 (2008).
232. Xiao L, Xu H, Zhang Y et al. Quetiapine facilitates oligodendrocyte development and prevents mice from myelin breakdown and behavioral changes. Mol. Psychiatry 13(7), 697-708 (2008). (Pubitemid 351861531)
233. Yamauchi T, Tatsumi K, Makinodan M et al. Olanzapine increases cell mitotic activity and oligodendrocyte-lineage cells in the hypothalamus. Neurochem. Int. 57(5), 565-571 (2010).
234. Rosin C, Colombo S, Calver AA, Bates TE, Skaper SD. Dopamine D2 and D3 receptor agonists limit oligodendrocyte injury caused by glutamate oxidative stress and oxygen/glucose deprivation. Glia 52(4), 336-343 (2005). (Pubitemid 43076225)
235. Konopaske GT, Dorph-Petersen KA, Sweet RA et al. Effect of chronic antipsychotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys. Biol. Psychiatry 63(8), 759-765 (2008). (Pubitemid 351400762)
236. Steiner J, Sarnyai Z, Westphal S et al. Protective effects of haloperidol and clozapine on energy-deprived OLN-93 oligodendrocytes. Eur. Arch. Psychiatry Clin. Neurosci. DOI: 10.1007/s00406- 011-0197-3 (2011) (Epub ahead of print).
237. Fernø J, Rader M, Vik-Mo A et al. Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action? Pharmacogenomics J. 5(5), 298-304 (2005). (Pubitemid 41486229)
238. Narayan S, Kass KE, Thomas EA. Chronic haloperidol treatment results in a decrease in the expression of myelin/oligodendrocyte-related genes in the mouse brain. J. Neurosci. Res. 85(4), 757-765 (2007). (Pubitemid 46426075)
239. Thomas EA, George RC, Danielson PE et al. Antipsychotic drug treatment alters expression of mRNAs encoding lipid metabolism-related proteins. Mol. Psychiatry 8(12), 983-993, 950 (2003). (Pubitemid 37523910)
240. Thomas EA, Danielson PE, Nelson PA et al. Clozapine increases apolipoprotein D expression in rodent brain: towards a mechanism for neuroleptic pharmacotherapy. J. Neurochem. 76(3), 789-796 (2001). (Pubitemid 32126079)
241. Navari S, Dazzan P. Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings. Psychol. Med. 39(11), 1763-1777 (2009).
242. Bartzokis G, Lu PH, Nuechterlein KH et al. Differential effects of typical and atypical antipsychotics on brain myelination in schizophrenia. Schizophr. Res. 93(1-3), 13-22 (2007). (Pubitemid 46830753)
243. Bartzokis G, Lu PH, Stewart SB et al. In vivo evidence of differential impact of typical and atypical antipsychotics on intracortical myelin in adults with schizophrenia. Schizophr. Res. 113(2-3), 322-331 (2009).
244. Christensen J, Holcomb J, Garver D. State-related changes in cerebral white matter may underlie psychosis exacerbation. Psychiatry Res. Neuroimaging 30, 71-78 (2004). (Pubitemid 38221558)
245. Garver DL, Holcomb JA, Christensen JD. Compromised myelin integrity during psychosis with repair during remission in drug-responding schizophrenia. Int. Neuropsychopharmacol. 11(1), 49-61 (2008).
246. Girgis RR, Diwadkar VA, Nutche JJ, Sweeney JA, Keshavan MS, Hardan AY. Risperidone in first-episode psychosis: a longitudinal, exploratory voxel-based morphometric study. Schizophr. Res. 82(1), 89-94 (2006). (Pubitemid 43202651)
247. Bartzokis G, Lu PH, Stewart SB et al. In vivo evidence of differential impact of typical and atypical antipsychotics on intracortical myelin in adults with schizophrenia. Schizophr. Res. 113(2-3), 322-331 (2009).
248. Orre K, Wennstrom M, Tingstrom A. Chronic lithium treatment decreases NG2 cell proliferation in rat dentate hilus, amygdala and corpus callosum. Prog. Neuropsychopharmacol. Biol. Psychiatry 33(3), 503-510 (2009).
249. Dill J, Wang H, Zhou F, Li S. Inactivation of glycogen synthase kinase 3 promotes axonal growth and recovery in the CNS. J. Neurosci. 28(36), 8914-8928 (2008).
250. Macritchie KA, Lloyd AJ, Bastin ME et al. White matter microstructural abnormalities in euthymic bipolar disorder. Br. J. Psychiatry 196(1), 52-58 (2010).
251. Manning SM, Talos DM, Zhou C et al. NMDA receptor blockade with memantine attenuates white matter injury in a rat model of periventricular leukomalacia. J. Neurosci. 28(26), 6670-6678 (2008).
252. Krivoy A, Weizman A, Laor L, Hellinger N, Zemishlany Z, Fischel T. Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: a preliminary study. Eur. Neuropsychopharmacol. 18(2), 117-121 (2008). (Pubitemid 350296846)
253. Afshar H, Roohafza H, Mousavi G et al. Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial. J. Psychopharmacol. 23(2), 157-162 (2009).
254. Skihar V, Silva C, Chojnacki A et al. Promoting oligodendrogenesis and myelin repair using the multiple sclerosis medication glatiramer acetate. Proc. Natl Acad. Sci. USA 106(42), 17992-17997 (2009).
255. Lavedan C, Volpi S, Polymeropoulos MH, Wolfgang CD. Effect of a ciliary neurotrophic factor polymorphism on schizophrenia symptom improvement in an iloperidone clinical trial. Pharmacogenomics 9(3), 289-301 (2008). (Pubitemid 351816766)
256. Tanaka Y, Ujike H, Fujiwara Y et al. Schizophrenic psychoses and the CNTF null mutation. Neuroreport 9(6), 981-983 (1998). (Pubitemid 28266608)
257. Kipnis J, Cohen H, Cardon M, Ziv Y, Schwartz M. T cell deficiency leads to cognitive dysfunction: implications for therapeutic vaccination for schizophrenia and other psychiatric conditions. Proc. Natl Acad. Sci. USA 101(21), 8180-8185 (2004). (Pubitemid 38698074)
258. Kipnis J, Cardon M, Strous RD, Schwartz M. Loss of autoimmune T cells correlates with brain diseases: possible implications for schizophrenia? Trends Mol. Med. 12(3), 107-112 (2006).
259. Bartzokis G. Schizophrenia: breakdown in the well-regulated lifelong process of brain development and maturation. Neuropsychopharmacol. 27, 672-683 (2002).
260. Peters A, Sethares C. Oligodendrocytes, their progenitors and other neuroglial cells in the aging primate cerebral cortex. Cereb. Cortex 14(9), 995-1007 (2004). (Pubitemid 39121361)
261. Peters A. Structural changes in the normally aging cerebral cortex of primates. Prog. Brain Res. 136, 455-465 (2002 (Pubitemid 35460999)